How Vitamin C May Help Cancer Treatments Work Better
April 14, 2017
New multiple sclerosis drug, backed by 40 years of research, could halt disease
April 14, 2017
Show all

Fresh battle over hepatitis C drug

Advocates in Europe aim to make hepatitis C medications more affordable.

Medical NGOs mounted a new legal bid on Monday to break a US pharma giant’s hold on a hepatitis C drug whose price — thousands of dollars for a typical course — has unleashed a fierce patent battle.

The drug, known by its lab name as sofosbuvir, cures 90 percent of Hep C cases, bringing hope for millions infected with the dangerous liver virus.

But critics say the manufacturer, Gilead Sciences, has priced it out of the reach of many patients and public health systems.

A single pill of the the drug, marketed as Sovaldi and other names, can cost up to $1,000 (R12,700). In France, a 12-week course of treatment costs 41,000 euros.

Read full article: Fresh battle over hepatitis C drug

Read Full Article: Fresh battle over hepatitis C drug

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.